{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"18.040","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"1,762,957,952","primaryexch":"香港交易所","ric":"9969.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BK8K0W3","am":"262.30","iv":"","ew_strike":"","as":"17.550","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"17.520","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-28 00:06:03.0","lo52":"5.020","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"崔霽松","underlying_ric":"688428.SS","hi52":"20.620","issuer_name":"諾誠健華醫藥有限公司","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"17.240","mkt_cap":"30.93","f_aum_hkd":null,"ew_sub_per_to":"","ls":"17.550","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.150","aum":"","issued_shares_class_B":null,"vo":"14.86","secondary_listing_flag":false,"listing_date":"2020年3月23日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"諾誠健華醫藥有限公司","nm_s":"諾誠健華","sym":"9969","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"諾誠健華醫藥有限公司是一家主要從事生物醫藥研發、生產和商業化的中國公司。該公司專注於腫瘤和自身免疫性疾病等存在巨大未滿足臨床需求的領域。該公司的主要產品管線包括奧布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其產品主要用於治療血液瘤、實體瘤和自身免疫病。該公司還在開髮用於治療由B細胞或T細胞功能異常所導致的自身免疫性疾病的產品。該公司主要在國內和國外市場開展業務。","op":"17.330","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港<br/>灣仔<br/>皇后大道東248號<br/>陽光中心40樓","pc":"-0.85","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"17.700","isin":"KYG4783B1032","moneyness":""}},"qid":"1759074066877"}
